Empaveli (PEGcetacoplan) Patent Expiration, LOE Window & CMS Spending

Empaveli (PEGcetacoplan) by Apellis: FDA Orange Book core substance LOE 2033-11-15 (last listed 2038-12-14), 0 AB generics, $39.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorApellis
FDA Application & PathwayN215014 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2033-11-15
Last Listed Patent or Exclusivity Date2038-12-14
Orange Book Patents (*PED Extensions)11 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$39.2M
2024 Medicare Part D Spend$28.6M
2024 Medicaid Spend$10.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel